His primary areas of investigation include Alzheimer's disease, Internal medicine, Dementia, Disease and Psychiatry. Alzheimer's disease is a primary field of his research addressed under Pathology. Stephen Salloway works mostly in the field of Internal medicine, limiting it down to concerns involving Placebo and, occasionally, Clinical trial.
His Dementia study combines topics from a wide range of disciplines, such as Hyperintensity and Pediatrics. The various areas that Stephen Salloway examines in his Disease study include Biomarker and Neuroscience. His work on Depression, Cognitive disorder and Apathy is typically connected to In patient as part of general Psychiatry study, connecting several disciplines of science.
Stephen Salloway spends much of his time researching Disease, Dementia, Internal medicine, Alzheimer's disease and Neuroscience. His research integrates issues of Biomarker, Cognition, Cerebrospinal fluid and Intensive care medicine in his study of Disease. His Dementia study integrates concerns from other disciplines, such as Positron emission tomography, Psychiatry, Neuroimaging and Pediatrics.
His work on Depression and Neuropsychiatry as part of general Psychiatry study is frequently linked to In patient, therefore connecting diverse disciplines of science. His Internal medicine research is multidisciplinary, incorporating elements of Placebo and Oncology. His study on Alzheimer's disease is covered under Pathology.
Stephen Salloway mainly focuses on Disease, Dementia, Internal medicine, Neuroscience and Alzheimer's disease. His Disease study combines topics in areas such as Clinical trial, Bioinformatics, Intensive care medicine, Biomarker and Atrophy. His research in Dementia intersects with topics in Differential item functioning and Functional impairment.
His studies in Internal medicine integrate themes in fields like Cognition, Oncology and Cardiology. His work in Neuroscience covers topics such as Neurodegeneration which are related to areas like Cerebrospinal fluid. His biological study focuses on Clinical Dementia Rating.
His main research concerns Disease, Dementia, Alzheimer's disease, Internal medicine and Neuroscience. His Disease research is multidisciplinary, incorporating perspectives in Atrophy, Clinical trial, Bioinformatics and Cerebrospinal fluid. In the subject of general Dementia, his work in Dementia research is often linked to Cultural diversity, thereby combining diverse domains of study.
His Alzheimer's disease study incorporates themes from Asymptomatic, Messenger RNA, Positron emission tomography, Pediatrics and Cohort. Stephen Salloway has included themes like Cognition and Oncology in his Internal medicine study. His work on Hippocampus, Stimulation, Hippocampal stimulation and Corpus callosum as part of general Neuroscience study is frequently linked to Deep brain stimulation, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease
Randall J. Bateman;Chengjie Xiong;Tammie L.S. Benzinger;Anne M. Fagan.
The New England Journal of Medicine (2012)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois;Bruno Dubois;Howard H Feldman;Claudia Jacova;Harald Hampel;Harald Hampel.
Lancet Neurology (2014)
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Jeff Sevigny;Ping Chiao;Thierry Bussière;Paul H Weinreb.
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway;Reisa Sperling;Nick C. Fox;Kaj Blennow.
The New England Journal of Medicine (2014)
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois;Harald Hampel;Harald Hampel;Howard H. Feldman;Philip Scheltens.
Alzheimers & Dementia (2016)
Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression
Donald A. Malone;Darin D. Dougherty;Ali R. Rezai;Linda L. Carpenter.
Biological Psychiatry (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
S. Salloway;R. Sperling;S. Gilman;N.C.I. Fox.
Three-Year Outcomes in Deep Brain Stimulation for Highly Resistant Obsessive–Compulsive Disorder
Benjamin D Greenberg;Donald A Malone;Gerhard M Friehs;Ali R Rezai.
Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience.
B D Greenberg;Lutgardis Gabriëls;D A Malone;A R Rezai.
Molecular Psychiatry (2010)
Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis
Y. Iturria-Medina;R. C. Sotero;P. J. Toussaint;J. M. Mateos-Pérez.
Nature Communications (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: